FDA 483 - Kyowa Kirin Co., Ltd. - August 30, 2021
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Kyowa Kirin Co., Ltd.'s Takasaki Plant, a drug substance manufacturer, revealed significant deficiencies across its quality systems. Observations included inadequate cleaning and sanitization programs, unvalidated electronic data systems lacking proper controls, and a failure to follow or establish adequate standard operating procedures. Additionally, the firm lacked assurance in cleaning procedure effectiveness, critical utility qualification, equipment qualification, and facility maintenance.
ID · 1f9e13fc-f3bd-4e84-a15c-87d3e56e3b7c